Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Thermo Finnigan, MDS Proteomics Will Jointly Develop FTMS Proteomics System

NEW YORK, May 9-Equipment manufacturer Thermo Finnigan and MDS Proteomics said today that they plan to work together to adapt mass spectrometry devices for the analysis of low-abundancy proteins.


The two companies will customize Thermo's Fourier transform ion cyclotron resonance mass spectrometry technology for use in identifying disease-specific proteins that may be present only in trace amounts.


MDS Proteomics will provide technical specifications, evalute and assess the equipment, and provide proteomics-specific expertise to guide instrument development. Thermo Finnigan will give MDS Proteomics exclusive beta-version access to the machines as they progress.


Thermo Finnigan will use this feedback in developing a commercial FTMS-based proteomics system that offers high dynamic range, ultra-high sensitivity and peptide sequencing capabilities in order to speed and improve detection of low-level proteins.


The company says that FTMS technology allows for a several thousand-fold boost in mass spectromic resolution and a 100-fold improvement in dynamic range detection of trace proteins.


Thermo Finnigan, a division of Thermo Electron, is based in San Jose, Calif.


MDS Proteomics is headquartered in Toronto.



The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.